Repare Therapeutics Inc (RPTX)

$1.65 -0.04 (-2.37%)
Market Cap 70.88M
Revenue (ttm) 53.48M
Net Income (ttm) -84.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -158.36%
Debt to Equity Ratio 0.00
Volume 3,077,500
Avg Vol 208,442
Day's Range N/A - N/A
Shares Out 42.96M
Stochastic %K 0%
Beta 1.06
Analysts Sell
Price Target $3.00

Company Profile

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 412 7018
Address:
7171 Frederick-Banting, Building 2, Suite 270 St-Laurent, Montreal, Canada
S2K_TP
S2K_TP Nov. 17 at 1:31 AM
🚨 PM topwatch - Nov. 17th, 2025 $GNS surged ~50% AH Friday following its announcement of a federal class action lawsuit against Citadel Securities and Virtu Americas, alleging long-term market manipulation. If $1.50 holds premarket, momentum continuation toward $1.80+ is in play. $RPTX RPTX surged ~30% after reporting break-even Q3 earnings, beating expectations of a -$0.35 loss and marking a major EPS surprise. $2.10 — key AH consolidation and psychological pivot. If it holds this level, $2.40+ becomes viable on open momentum. $QUBT surged 14% following its first-ever quarterly profit and a 280% YoY revenue spike — a strong catalyst that could fuel a continued move toward $13+ this week if momentum holds.
0 · Reply
PaulLaurent
PaulLaurent Nov. 16 at 7:50 PM
🌅 4:00am EST Watchlist $GNS – Filed a federal securities class-action tied to alleged market manipulation. Watch scope of claims, defendant list, and any injunctive relief; headline volatility likely. $RPTX – Entered a definitive agreement to be acquired. Track deal price/structure, regulatory timeline, and spread behavior into close. $NAMM – AH runner. Monitor premarket volume, VWAP reclaims, and prior HOD retests. $DFLI – Q3 print out. Focus on margin cadence, battery demand across RV/marine/off-grid, channel/OEM updates, and guidance. $CYPH – Potential multi-day runner. Favor VWAP holds, liquidity expansion, and clean pullback entries. Tone: Litigation, M&A, and earnings headlines lead. Favor VWAP/pivot reclaims, trim into strength, keep risk tight.
0 · Reply
MOOO1001
MOOO1001 Nov. 16 at 6:12 PM
$RPTX Monday 6$
0 · Reply
Ric_1M
Ric_1M Nov. 15 at 3:08 PM
$GNS $RPTX $CWAN $NAMM $DFLI “Choose a leader who will invest in building bridges, not walls. Books, not weapons. Morality, not corruption. Intellectualism and wisdom, not ignorance.” Suzy Kassem
1 · Reply
LabPsycho
LabPsycho Nov. 15 at 3:05 PM
$RPTX @Windy007 That's they way I interpret all these rarely every materialize 'potential' for multi billion $$ milestone payments that some biotechs get when partnering with big pharma but never materialize. Its all fluff and window dressing.... i.e. Big pharma could have bought little Biotech A for 3 X current share price (lets say 200 million) but instead gives them $$25M upfront but with the promise to pay a potential 2 billion in milestones. NOPE! If they actually thought they would have to pay a fraction of those milestones, they just would have bought Biotech A outright. Don't be deceived.
0 · Reply
P_etheris
P_etheris Nov. 15 at 6:34 AM
$RPTX I loved this Friday 💪🏻 First I caught almost the bottom of $ORCL with 476 shares @211.24 and then, in the last minute of open market decided after an HOUR OF DD, buy this ☝️ Check Q2 transcript for CVR!!! I believe Lunresertib will easily PROVIDE ☝️
0 · Reply
StockScanners
StockScanners Nov. 15 at 4:01 AM
$RPTX keep watch if this holds above 1.97
0 · Reply
SecondChances
SecondChances Nov. 15 at 2:12 AM
$RPTX I will consider selling only if that CVR is priced north of $1.00. Otherwise I keep the CVR. Any licensing happens before closing, the CVR gets 100%, if the licensing happens after closing, it gets 50%. Debiopharm deal falls in first category, the others may fall in 2nd but Xeno is buying the drugs only because they see the value.
1 · Reply
DaBullRunner
DaBullRunner Nov. 15 at 1:14 AM
🏆 ANOTHER SOLID DAY TO END THE WEEK 🏆 If you’re reading this just know that there are opportunities to make LIFE CHANGING gains EVERY DAY Bull market, Bear market… it doesn’t matter This market lately is designed to have 100% runners almost consistently You just need to know how to play the game and be in the know BEFORE the crowd And doing this for well over 20 years has given me the tools to understand the market behavior You seen my results I have NOTHING to prove Now my focus shifts to YOU I want to CHANGE lives I have changed many lives There is no feeling like it And I’m here to do it again So LETS GO!!!!!!!!! I wish each one of you reading this a successful new year, and beyond ❤️ $GNS $RPTX $DFLI $NAMM $QUBT see you all on Monday!
0 · Reply
AlertsAndNews
AlertsAndNews Nov. 15 at 12:25 AM
Gappers here in after hours trading $GNS $RPTX $DTSS $CWAN $WSHP Happy Friday, here's to a great week! 🍻
1 · Reply
Latest News on RPTX
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

Nov 14, 2025, 4:44 PM EST - 2 days ago

Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 4 weeks ago

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 8, 2025, 7:00 AM EDT - 3 months ago

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

Jul 15, 2025, 4:05 PM EDT - 4 months ago

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:05 PM EDT - 6 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

May 1, 2025, 7:00 AM EDT - 7 months ago

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

May 1, 2025, 7:00 AM EDT - 7 months ago

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 7 months ago

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Announces Leadership Transitions

Mar 31, 2025, 4:39 PM EDT - 8 months ago

Repare Therapeutics Announces Leadership Transitions

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 7, 2025, 4:05 PM EST - 9 months ago

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 7:05 AM EST - 9 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Jan 9, 2025, 4:05 PM EST - 11 months ago

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Dec 13, 2024, 12:09 PM EST - 1 year ago

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Dec 12, 2024, 4:20 PM EST - 1 year ago

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Dec 10, 2024, 4:05 PM EST - 1 year ago

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Nov 12, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Oct 23, 2024, 6:05 AM EDT - 1 year ago

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Oct 14, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Sep 30, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Sep 23, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Aug 30, 2024, 6:13 PM EDT - 1 year ago

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 27, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Jun 26, 2024, 10:30 AM EDT - 1 year ago

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Jun 10, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

May 29, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Repare Therapeutics Appoints Steven H. Stein, M.D.

Apr 26, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Appoints Steven H. Stein, M.D.

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Mar 21, 2024, 10:00 AM EDT - 1 year ago

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

Feb 15, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

Repare Therapeutics to Regain Global Rights to Camonsertib

Feb 12, 2024, 4:05 PM EST - 1 year ago

Repare Therapeutics to Regain Global Rights to Camonsertib

Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment

Jan 25, 2024, 7:00 AM EST - 1 year ago

Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Jan 8, 2024, 7:00 AM EST - 2 years ago

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Jan 4, 2024, 4:10 PM EST - 2 years ago

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

S2K_TP
S2K_TP Nov. 17 at 1:31 AM
🚨 PM topwatch - Nov. 17th, 2025 $GNS surged ~50% AH Friday following its announcement of a federal class action lawsuit against Citadel Securities and Virtu Americas, alleging long-term market manipulation. If $1.50 holds premarket, momentum continuation toward $1.80+ is in play. $RPTX RPTX surged ~30% after reporting break-even Q3 earnings, beating expectations of a -$0.35 loss and marking a major EPS surprise. $2.10 — key AH consolidation and psychological pivot. If it holds this level, $2.40+ becomes viable on open momentum. $QUBT surged 14% following its first-ever quarterly profit and a 280% YoY revenue spike — a strong catalyst that could fuel a continued move toward $13+ this week if momentum holds.
0 · Reply
PaulLaurent
PaulLaurent Nov. 16 at 7:50 PM
🌅 4:00am EST Watchlist $GNS – Filed a federal securities class-action tied to alleged market manipulation. Watch scope of claims, defendant list, and any injunctive relief; headline volatility likely. $RPTX – Entered a definitive agreement to be acquired. Track deal price/structure, regulatory timeline, and spread behavior into close. $NAMM – AH runner. Monitor premarket volume, VWAP reclaims, and prior HOD retests. $DFLI – Q3 print out. Focus on margin cadence, battery demand across RV/marine/off-grid, channel/OEM updates, and guidance. $CYPH – Potential multi-day runner. Favor VWAP holds, liquidity expansion, and clean pullback entries. Tone: Litigation, M&A, and earnings headlines lead. Favor VWAP/pivot reclaims, trim into strength, keep risk tight.
0 · Reply
MOOO1001
MOOO1001 Nov. 16 at 6:12 PM
$RPTX Monday 6$
0 · Reply
Ric_1M
Ric_1M Nov. 15 at 3:08 PM
$GNS $RPTX $CWAN $NAMM $DFLI “Choose a leader who will invest in building bridges, not walls. Books, not weapons. Morality, not corruption. Intellectualism and wisdom, not ignorance.” Suzy Kassem
1 · Reply
LabPsycho
LabPsycho Nov. 15 at 3:05 PM
$RPTX @Windy007 That's they way I interpret all these rarely every materialize 'potential' for multi billion $$ milestone payments that some biotechs get when partnering with big pharma but never materialize. Its all fluff and window dressing.... i.e. Big pharma could have bought little Biotech A for 3 X current share price (lets say 200 million) but instead gives them $$25M upfront but with the promise to pay a potential 2 billion in milestones. NOPE! If they actually thought they would have to pay a fraction of those milestones, they just would have bought Biotech A outright. Don't be deceived.
0 · Reply
P_etheris
P_etheris Nov. 15 at 6:34 AM
$RPTX I loved this Friday 💪🏻 First I caught almost the bottom of $ORCL with 476 shares @211.24 and then, in the last minute of open market decided after an HOUR OF DD, buy this ☝️ Check Q2 transcript for CVR!!! I believe Lunresertib will easily PROVIDE ☝️
0 · Reply
StockScanners
StockScanners Nov. 15 at 4:01 AM
$RPTX keep watch if this holds above 1.97
0 · Reply
SecondChances
SecondChances Nov. 15 at 2:12 AM
$RPTX I will consider selling only if that CVR is priced north of $1.00. Otherwise I keep the CVR. Any licensing happens before closing, the CVR gets 100%, if the licensing happens after closing, it gets 50%. Debiopharm deal falls in first category, the others may fall in 2nd but Xeno is buying the drugs only because they see the value.
1 · Reply
DaBullRunner
DaBullRunner Nov. 15 at 1:14 AM
🏆 ANOTHER SOLID DAY TO END THE WEEK 🏆 If you’re reading this just know that there are opportunities to make LIFE CHANGING gains EVERY DAY Bull market, Bear market… it doesn’t matter This market lately is designed to have 100% runners almost consistently You just need to know how to play the game and be in the know BEFORE the crowd And doing this for well over 20 years has given me the tools to understand the market behavior You seen my results I have NOTHING to prove Now my focus shifts to YOU I want to CHANGE lives I have changed many lives There is no feeling like it And I’m here to do it again So LETS GO!!!!!!!!! I wish each one of you reading this a successful new year, and beyond ❤️ $GNS $RPTX $DFLI $NAMM $QUBT see you all on Monday!
0 · Reply
AlertsAndNews
AlertsAndNews Nov. 15 at 12:25 AM
Gappers here in after hours trading $GNS $RPTX $DTSS $CWAN $WSHP Happy Friday, here's to a great week! 🍻
1 · Reply
Sixth_Sense
Sixth_Sense Nov. 14 at 11:40 PM
$RPTX bittersweet
0 · Reply
LiquiditySweepTrader
LiquiditySweepTrader Nov. 14 at 11:27 PM
$RPTX Top after hours stock!!!
0 · Reply
ikkydiphoenix
ikkydiphoenix Nov. 14 at 10:54 PM
$RPTX i've literally got all my shares at the very bottom, and considering i will have a stream of revenue for the next 10 years i think i will never trade my cvr for whatever premium price the market will trade shares until the deal is completed
0 · Reply
newbulloh2
newbulloh2 Nov. 14 at 10:43 PM
$RPTX no massive dip selloff what the deuce!
0 · Reply
DARKP00L
DARKP00L Nov. 14 at 10:39 PM
$RPTX 17:05 on Nov. 14 2025 Trading Halt: Halt status updated at 5:05:00 PM ET: Quotation Resumption: News and Resumption Times #tradeideas
0 · Reply
Zackpedia
Zackpedia Nov. 14 at 10:38 PM
$RPTX Selling time at 2.17
0 · Reply
Intradaytrade100
Intradaytrade100 Nov. 14 at 10:35 PM
$RPTX obviously there will be a bidding war....how high will it go????
1 · Reply
Intradaytrade100
Intradaytrade100 Nov. 14 at 10:32 PM
$RPTX bidding war to ensue... $3.00 maybe??????
0 · Reply
DARKP00L
DARKP00L Nov. 14 at 10:24 PM
$RPTX this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
Tradebub
Tradebub Nov. 14 at 10:21 PM
$RPTX It is not that simple. Add at least $0.50
0 · Reply
_CCS_
_CCS_ Nov. 14 at 10:16 PM
$RPTX easy short to 1.83 lol
0 · Reply
hsfjhv
hsfjhv Nov. 14 at 10:16 PM
$RPTX as per ChatGPT
1 · Reply